Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial

Erick Marcet Santiago de Macedo, Rachel Camargo Carneiro, Patricia Picciarelli de Lima, Breno Gonçalves Silva, Suzana Matayoshi, Erick Marcet Santiago de Macedo, Rachel Camargo Carneiro, Patricia Picciarelli de Lima, Breno Gonçalves Silva, Suzana Matayoshi

Abstract

Background: The recurrence rate of periocular nodular basal cell carcinoma (PNBCC) following treatment with imiquimod (IMQ) has not yet been established. Previous studies did not include histological follow-up. The aim of this analysis was to evaluate the efficacy of topical immunotherapy with 5% IMQ cream for the treatment of PNBCC.

Study design: A prospective, non-randomized, and uncontrolled longitudinal case series study. No participants were blinded. Punch biopsy confirmed PNBCC patients were included at the Ophthalmology Clinic of São Paulo University Medicine School Hospital (from 2008 to 2012). Patients were treated with 5% IMQ cream once a day, 5 days per week, for 8-16 weeks. Standard lesion photographic documentation was done during the study. Three months after treatment ended, an image-guided biopsy was performed. Patients were followed at 6-month intervals and annually for control biopsies. Main outcome measures were clinical and histological clearance rates. Data were analysed by frequency distribution for qualitative group characteristics and central tendency measures for quantitative data.

Results: Twenty-four patients met the inclusion criteria, 19 of whom remained until the end of treatment. The histological clearance rate was 89.5% and 84.2%, respectively, at 3 and 39.5 months. The 3-year histological clearance rate was 81.8% (9/11) for lesions >10 mm, and 100% (8/8) for lesions <10 mm. Three patients did not tolerate the side effects of the medication and left the study. Two patients were excluded for treatment interruption related to comorbidities.

Conclusions: Our results indicated that 5% IMQ cream was a useful alternative treatment for NBBCC, especially for lesions <10 mm. IMQ also showed a significant neoadjuvant effect on lesions >10 mm.

Trial registration: ClinicalTrial.gov Registration Dec 3, 2008: # NCT 00803907.

Trial registration: ClinicalTrials.gov NCT00803907.

Figures

Figure 1
Figure 1
Imiquimod (IMQ) treatment flow chart.
Figure 2
Figure 2
Lesion #12. Nodular basal cell carcinoma in the medial canthus. A) before treatment, B) local inflammation mimicking preseptal cellulitis, C) 2 years after treatment completion, when the biopsy identified BCC recurrence.
Figure 3
Figure 3
Clinical pictures before and 3 years after treatment. A) Case #13: Eyelid margin PNBCC, B) after treatment, C) case #4, medial canthus PNBCC, D) after treatment.

References

    1. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol. 2006;19(Suppl 2):S127–147. doi: 10.1038/modpathol.3800512.
    1. Collins GL, Nickoonahand N, Morgan MB. Changing demographics and pathology of nonmelanoma skin cancer in the last 30 years. Semin Cutan Med Surg. 2004;23:80–3. doi: 10.1016/S1085-5629(03)00089-0.
    1. Allali J, D’Hermies F, Renard G. Basal cell carcinomas of the eyelids. Ophthalmologica. 2005;219:57–71. doi: 10.1159/000083263.
    1. McGuire JF, Ge NN, Dyson S. Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior. Am J Otolaryngol. 2009;30:121–133. doi: 10.1016/j.amjoto.2008.03.002.
    1. Smith V, Walton S. Treatment of facial Basal cell carcinoma: a review. J Skin Cancer 2011; doi 10.1155_2011_380371
    1. Bøgelund FS, Philipsen PA, Gniadecki R. Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm Venereol. 2007;87:330–4. doi: 10.2340/00015555-0236.
    1. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722–33. doi: 10.1016/j.jaad.2003.11.066.
    1. Eigentler TK, Kamin A, Weide BM, Breuninger H, Caroli UM, Möhrle M, et al. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. J Am Acad Dermatol. 2007;57:616–21. doi: 10.1016/j.jaad.2007.05.022.
    1. Blasi MA, Giammaria D, Balestrazzi E. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am J Ophthalmol. 2005;140:1136–9. doi: 10.1016/j.ajo.2005.06.057.
    1. Choontanom R, Thanos S, Busse H, Stupp T. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol. 2007;245:1217–20. doi: 10.1007/s00417-007-0561-1.
    1. Prokosch V, Thanos S, Spaniol K, Stupp T. Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids. Graefes Arch Clin Exp Ophthalmol. 2011;249:121–5. doi: 10.1007/s00417-010-1526-3.
    1. Leppala J, Kaarniranta K, Uusitalo H, Kontkanen M. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand. 2007;85:566–8. doi: 10.1111/j.1755-3768.2007.00896.x.
    1. Garcia-Martin E, Idoipe M, Gil LM, Pueyo V, Alfaro J, Pablo LE, et al. Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas. J Ocul Pharmacol Ther. 2010;26:373–9. doi: 10.1089/jop.2010.0030.
    1. Image J [] acessed 12 Oct 2008
    1. Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147:1227–36. doi: 10.1046/j.1365-2133.2002.05069.x.
    1. Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138:1165–71. doi: 10.1001/archderm.138.9.1165.
    1. Carneiro RC, de Macedo EM, Matayoshi S. Imiquimod 5% cream for the treatment of periocular Basal cell carcinoma. Ophthal Plast Reconstr Surg. 2010;26:100–2. doi: 10.1097/IOP.0b013e3181b8dd71.
    1. Peris K, Campione E, Micantonio T, Marulli GC, Fargnoli MC, Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial. Dermatol Surg. 2005;31:318–23. doi: 10.1097/00042728-200503000-00012.
    1. García Martín E, Fernández Tirado FJ. Periocular basal cell carcinoma treatment tendencies. Arch Soc Esp Oftalmol. 2010;85:261–2. doi: 10.1016/j.oftal.2010.09.008.
    1. Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Maus J, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18(6):677–82.
    1. Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PS, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2015;15:96–105. doi: 10.1016/S1470-2045(13)70530-8.
    1. Carneiro RC, de Macedo EM, de Lima PP, Bonatti R, Matayoshi S. Is 2-mm punch biopsy useful in the diagnosis of malignant eyelid tumors? Ophthal Plast Reconstr Surg. 2012;28:282–5. doi: 10.1097/IOP.0b013e31825a65b4.
    1. Cannon PS, O’Donnell B, Huilgol SC, Selva D. The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions. Br J Ophthalmol. 2011;95:1682–5. doi: 10.1136/bjo.2009.178202.
    1. Levin F, Khalil M, McCormick SA, Della Rocca D, Maher E, Della Rocca RC. Excision of periocular basal cell carcinoma with stereoscopic microdissection of surgical margins for frozen-section control: report of 200 cases. Arch Ophthalmol. 2009;127:1011–15. doi: 10.1001/archophthalmol.2009.222.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner